Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

SDS offers -2x S&P 500 exposure with lower decay than peers, useful for tactical hedging if actively monitored. Learn why SDS ...

Here in the U.S., many startups are facing hard questions about how they’ve grown: bloated valuations, misaligned incentives, shallow product pipelines. The contrast with Korea’s quiet biotech ascent ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

We assign Veeva’s commercial solutions a wide moat based on customer switching costs. Veeva CRM is Veeva’s cloud-based customer relationship management platform. It markets to pharmaceutical and ...

Zai Lab accelerates innovative drug launches in China through partnerships and expertise, targeting $1.5-$2B revenue by 2028.

Entrepreneur and politician Vivek Ramaswamy made much of his fortune founding biotechnology companies and trading their stocks, but now the former GOP presidential candidate and current contender for ...

Discover the key biotech trends moving the industry forward in Europe at a time when there lies uncertainty in global ...

Eikon Therapeutics announces layoffs, cutting 55 jobs due to reduced federal funding and biotech investment challenges.

A Bay Area biotech company that laid off dozens of people this week has blamed the job cuts on policies of the Trump ...

Eikon Therapeutics, a Bay Area biotech startup with $1.1 billion in funding, is laying off dozens of employees and pointing ...